411
Views
30
CrossRef citations to date
0
Altmetric
Review

Management of asthma in the elderly patient

Pages 913-922 | Published online: 15 Jul 2013

Abstract

A significant number of older asthmatics, more often than in previous ages, have poorly controlled asthma, leading to increased morbidity and mortality. On the other hand, current guidelines suggest that most asthmatics can obtain achievement and maintenance of disease control and do not include sections specific to the management of asthma in the elderly so that it is more evident the contrast between poor control of asthma in the elderly and the lack of specific guidance from guidelines on asthma management in older asthmatics. Inhaled corticosteroids are the cornerstone for older asthmatics, eventually with add-on inhaled long-acting beta-agonists; inhaled short acting beta-agonists can be used as rescue medications. Triggers exacerbating asthma are similar for all ages, but inhaled viruses and drug interactions have greater clinical significance in the elderly. Older asthmatics have an increased likelihood of comorbidities and polypharmacy, with possible worsening of asthma control and reduced treatment adherence. Physicians and older asthmatics probably either do not perceive or accept a poor asthma control. We conclude that specific instruments addressed to evaluate asthma control in the elderly with concomitant comorbidities and measurements for improving self-management and adherence could assure better disease control in older asthmatics.

Introduction

Asthma is a chronic inflammatory bronchial disease associated with airway hyperresponsiveness, variable airflow obstruction, and episodes of wheezing, breath-lessness, and cough; although these symptoms are common to many other diseases, in asthma they have a marked variability in response to a range of environmental stimuli, such as inhaled viruses, allergens, and drugs, often permitting the suspicion of diagnosis on a clinical basis (see ).Citation1Citation5

Table 1 Diagnosis of asthma based on medical history, physical examination, and objective measurementsCitation1Citation4

Asthma is widespread for all classes of age, including the elderly. The term elderly usually refers to persons aged 65 years or older, a largely increasing population worldwide. The physician-diagnosed prevalence of asthma in older adults is between 6% and 10%, just as in any other age group.Citation6 Asthma in older adults is either diagnosed after the age of 65 years or with a history of long-standing disease. In a cohort study of 1485 older asthmatics recruited by chest physicians, almost a quarter were diagnosed after 65 years.Citation7

The goal of asthma treatment is achievement and maintenance of disease control.Citation1Citation5 Uncontrolled asthma is more common in older adults than in previous ages with a substantial clinical burden, a greater proportion of asthma medications prescriptions, hospitalizations, and death.Citation8Citation13

The aim of this study is to assess the current modalities of asthma management in the elderly with reference to causes of uncontrolled disease and possible adjustments. Management of acute asthma is beyond the scope of the present work and interested readers are referred to other reviews.Citation1Citation4

This review includes results from the literature judged to be relevant on the topic. The PubMed database was searched using the keywords “asthma” in combination with “elderly” or “aging” or “older” up to March 2013. The selection of articles was not systematic. Studies were not graded by criteria defined a priori.

Asthma control

Guidelines emphasize the need to use disease control to base adjustments on treatment for all ages.Citation1Citation5 With slight differences among guidelines,Citation14 asthma control is usually established using some clinical and physiological outcomes assessed by the patient’s recall of the previous 4 weeks, as shown in . Likewise, although the concept of asthma control is the same for all ages, its proper recognition in the elderly may be complicated because older asthmatics have a reduced perception of bronchoconstriction,Citation15,Citation16 tend to attribute cough or exertional breathlessness to age alone,Citation17,Citation18 and confuse symptoms of asthma with those of other chronic concomitant comorbidities, such as chronic obstructive pulmonary disease (COPD) and heart failure.Citation19 Some questionnaires, mainly based on some clinical variables, can help clinicians to assess asthma control. However, they are validated in a range of ages, but not specifically in the elderly.Citation20Citation22 Other variables, namely treatment side effects, frequency and severity of exacerbations, and decline in lung function are also used for a full evaluation of disease control, but require longer observation over time.Citation1Citation5 Some physiologic measurements, such as peak expiratory fow monitoring, are used to evaluate asthma control, although offer no advantage over symptoms monitoring in older adults with moderate to severe asthma.Citation23 Monitoring with spirometry is underused in the elderly.Citation8 Other variables, such as fractional exhaled nitric oxide measurements, are not routinely useful for assessing asthma control, at least in the elderly.Citation24

Table 2 Classification of asthma control according to guidelinesCitation3

Guidelines recommend a stepwise approach for management according to the individualized assessment of asthma control, as shown in . At each step, a preferred option and alternatives are identified: when asthma is uncontrolled, treatment is required to be increased to the next step; by contrast, when asthma is controlled, a reduction in the amount of treatment may be organized.Citation1Citation5 This process requires that asthma control is monitored by health care professionals and, preferably, by the patient at regular intervals.Citation19 The frequency of follow-up assessments depends upon the patient’s initial clinical severity and the patient’s confidence in playing a role in his/her ongoing asthma control (self-management). Typically, patients are seen 1–3 months after the initial visit and every 3 months thereafter, but the interval is shorter after an exacerbation. A document specifically created to manage older asthmatics confirms these recommendations.Citation25

Table 3 Stepwise approach to asthma therapyCitation1Citation4

Inhaled corticosteroids

Inhaled corticosteroids (ICS) are the cornerstone of asthma anti-inflammatory therapy. Guidelines recommend regular daily long-term ICS use for all subjects with uncontrolled or partly controlled asthma.Citation1Citation5 In these conditions, several studies have demonstrated the efficacy of ICS in assuring asthma control.Citation5,Citation26 The decision of proper ICS dosing is based on the clinician’s judgment of the response to treatment.Citation1Citation5 However, most benefits are achieved in adults at relatively low doses, equivalent to 0.2–0.4 mg of beclomethasone dipropionate (BDP) or equivalent per day that seldom sustain systemic effects even for long-term regular use.Citation27 Increasing to higher doses provides relatively little further benefit in terms of asthma control, but increases the risk of side effects.Citation27 The estimated comparative daily doses of different ICS through inhalers are reported in .Citation1Citation5 Different ICS may marginally influence safety and effectiveness by several factors, such as oral bioavailability, different pharmacokinetics, and on-site activation into the lung.Citation29 ICS are usually delivered via inhalers, either metered dose inhalers (MDI) or dry powder inhalers (DPI); although ICS can also be nebulized, this method of delivery is seldom used as current formulations are available as suspensions that have poor and variable lung drug delivery.Citation30 Recently, the replacement of MDI propellants with more ecological formulations has permitted the modification of the characteristics of some ICS, delivering extra fine particles and increasing lung drug delivery; perhaps targeting smaller airways, some studies of real-life use attribute some advantages to these extra fne ICS with respect to traditional MDI, even at equipotent doses.Citation31Citation33 ICS do not cure asthma and when they are discontinued, deterioration of control follows within weeks to months in most patients.Citation34 However, not all asthmatics respond to ICS; failure of ICS treatment occurs in up to 25%–35% of patients.Citation28 Asthmatic phenotypes characterized by neutrophilic inflammation of the airways are less likely to respond to ICS than those with prevalent eosinophilic inflammation.Citation35 In older asthmatics neutrophilic airway inflammation is more common than in previous ages.Citation36 Likewise, although extensive specific information is not available, clinical studies do not support that ICS in older adults have less efficacy than in younger ages.Citation5 Probably, in real life nonadherence to ICS is a more important problem and particularly in older asthmatics.Citation19 In a large US survey, elderly asthmatics received a greater under-treatment of ICS than previous ages.Citation37 Most older patients admitting to emergency departments for asthma symptoms were not using ICS.Citation10 In another group of 6254 elderly adults consecutively admitted to hospital with asthma in Ontario, those patients identified as users of ICS post-discharge were respectively 29% readmitted referrals to hospital and 30% of those who died over a 1-year follow-up period.Citation38

Table 4 Estimated comparative daily dose of different ICS in milligrams for adults based upon the available efficiency data in the literature

Inhaled beta-agonists

Inhaled β2-agonists are the most effective reliever in asthma.Citation1Citation5 According to the duration of action, they are classified into either short-acting β2-agonists (SABAs) or long-acting β2-agonists (LABAs). Albuterol is by far the most commonly used SABA. Formoterol and salmeterol are the most commonly used LABAs. Formoterol, like albuterol, is a fast-acting reliever. Albuterol and (in some countries) formoterol are not only available by inhalation, but also by nebulization. There is no clinical difference between different devices for β2-agonists’ delivery.Citation39 However, inhalers are less cumbersome and more convenient than nebulizers and preferred if proper inhaler technique is obtained.

The number of β2-adrenergic receptors on the smooth airway muscles decrease with aging.Citation40 The response to SABAs has been shown to decline with ageCitation41 and older asthmatics admitting to emergency rooms may be less responsive to albuterol than younger asthmatics.Citation10 By contrast, current studies do not support that LABA use in older adults is less effective than in younger ages.Citation1Citation5

Guidelines recommend that asthmatics should have access to an inhaled fast-acting bronchodilator for rescue from acute symptoms.Citation1Citation5 SABAs should not be utilized more than 2–3 times a week because regular use of SABAs alone is dangerous.Citation42 LABAs should never be used alone as long-term regular monotherapy for asthma because they may be dangerous.Citation43,Citation44 When a low to medium ICS dose alone is unable to control asthma, the addition of an LABA has advantageous effects on lung function, symptoms, and exacerbations.Citation45 LABAs and ICS can be administered either separately or combined. Manufacturers have produced a combination of LABAs and ICS in a single inhaler, suggesting that it can optimize adherence with respect to separate inhaler use.Citation46,Citation47 Effectively, they ensure that LABAs are necessarily accompanied by ICS and their use is now widespread in real life. Even if used concomitantly with ICS, adverse effects of LABAs are not necessarily a nonissueCitation48 and they should be stopped when possibile.Citation49 Concerns remain about the ultimate major cardiovascular safety of LABAs. Nevertheless, minor adverse outcomes are common in older asthmatics using LABA/ICS combinations at daily recommended dosages: a survey found that, 41% and 51% of patients reported side effects attributed to ICS and LABA, respectively; the most common side effects were voice changes, sore throat, and tremors.Citation50

LABAs/ICS are currently used as a twice – daily regimen, but efforts have been made to develop a once-daily combination to simplify treatment and, possibly, increase adherence: indacaterol/mometasone, and vilanterol/fluticasone furoate are being developed and are two possible options.

Leukotriene receptor antagonists

Several studies have demonstrated that leukotriene receptor antagonists (LTRAs) are well tolerated and improve asthma control at all ages,Citation51 including the elderly.Citation52 LTRAs seem to be particularly useful in asthmatics with concomitant rhinitis,Citation53 and who smoke.Citation54 Once-daily orally administered montelukast is the most prescribed LTRA. When used alone, LTRAs are not as effective as ICS,Citation51 but they are the first alternative to ICS in older asthmatics who prefer a nonsteroid drug or who cannot tolerate ICS. LTRAs are used as an alternative to LABAs in addition to ICS, but the combination treatment of LABAs/ICS has more efficacy.Citation55 Recently, LTRAs have been proposed in the elderly with difficult-to-treat asthma for steroid resistance.Citation11

Biological agents

Several biological agents are in advanced phases of study in asthma, but only omalizumab, a monoclonal antibody directed against serum immunoglobulin E (IgE), is currently a therapeutic option in severe asthmatics,Citation56 including the elderly.Citation57 Omalizumab is used as add-on therapy in allergic patients with elevated serum levels of IgE and severe asthma uncontrolled with high doses of ICS, or requiring systemic corticosteroids, where it reduces the incidence of exacerbations, emergency room visits, and improves quality of life.Citation56 Omalizumab is administered as a subcutaneous injection every 2 to 4 weeks depending on dose. Its cost is higher than that of other asthma therapies. There is no evidence of a persistent beneficial effect after stopping its use.Citation58 It has marked variability in response, being, to date, not clear what differentiates a responder from a nonresponder. The most common side effects of omalizumab are local symptoms at the site of injection, and with a small risk of anaphylaxis, corresponding to 0.09% of cases in postmarketing surveillance studies.Citation59

Systemic corticosteroids

A goal of asthma management is to achieve disease control with no or minimal use of systemic corticosteroids. In fact, although systemic corticosteroids are very effective in asthma, their prolonged use is limited by the risk of significant adverse effects, such as adrenal failure, osteoporosis, diabetes mellitus, cataract, glaucoma, hypertension, psychosis, skin bruising, muscle weakness, gastritis, and peptic ulcer that warrant caution and monitoring.Citation1Citation4 However, long-term systemic corticosteroid use is sometimes required for severely uncontrolled asthma or as a burst to treat exacerbations. To this aim, oral prednisolone at daily dose of 0.5–1.0 mg/kg or equivalent is often given for at least 5 days,Citation4,Citation60 but the doses and duration should be individualized based on previous or current response. In addition, corticosteroids are also used for controlling a variety of diseases and in the elderly their weaning is a bigger challenge than in younger ages. Tapering is necessary after long-term use or recurrent bursts with systemic corticosteroids. Out of emergency oral preparations are preferred to intravenous and intramuscular formulations because they are equally effective and more practical.

Inhaled anticholinergics

Inhaled ipratropium, the most commonly used short-acting anticholinergic, is not a first-choice as a reliever, being less effective than β2-agonists. However, some elderly patients have a particularly good response to anticholinergics.Citation61 In uncontrolled asthma, despite ICS/LABA use, the addition of once-daily tiotropium may give a significant improvement in forced expiratory volume in 1 second (FEV1) and symptoms.Citation62 In many countries, tiotropium is available with either the DPI HandiHaler® (Pfizer, Inc, New York, NY, USA) or the soft mist inhaler Respimat® (Boehringer Ingelheim, Ingelheim, Germany). However, the release of tiotropium via Respimat has been associated with an increase in deaths, mainly in the elderly with known cardiac rhythm disorders, so it is advisable to use the DPI for its delivery until the current concerns are excluded.Citation63 Possibly, tiotropium and other long-term anticholinergics might be useful as add-on treatment in moderate to severe asthma, but currently their use is off-label and has not yet translated into specific treatment guidelines.Citation62

Other treatments

Theophyllines, usually used as oral sustained-release formulations, are a third-choice, but may provide a benefit as add-on therapy in patients who do not achieve control with ICS/LABAs.Citation1Citation3 They have a relatively small therapeutic index with significant side effects, particularly at higher doses and in the elderly.Citation25

Long-term use of macrolides is gaining popularity in neutrophilic forms of difficult-to-treat asthma.Citation64Citation66 It is not clear if the beneficial effect of macrolides is due to antibiotic or immunomodulatory effects.

Roflumilast, a phosphodiesterase-4 inhibitor with anti-inflammatory properties, has shown some efficacy with tolerable gastrointestinal side effects in patients with mild to moderate asthma.Citation67 Further trials are necessary to determine its role in asthma treatment.

Immunosuppressers, such as methotrexate, cyclosporins, tacrolimus, azathioprine, and gold salts are seldom used in asthma because they sustain a variety of side effects that usually do not offset their steroid-sparing effect.Citation3

Bronchial thermoplasty is a relatively safe bronchoscopic procedure in which radiofrequency energy is used to reduce bronchial smooth muscle wall thickness. If more clinical data will confirm its potential, bronchial thermoplasty might eventually become an option in severe asthma resistant to pharmacological management.Citation68

Trigger avoidance and the role of comorbidities

Allergy has a well-known role in asthma, even if, overall, it seems to wane with age.Citation69,Citation70 However, asthma in the elderly may be associated with allergic triggers.Citation70 There is scarce evidence about whether measures to create a low-allergen environment are effective for improving asthma control in the elderly. The role of specific immunotherapy in elderly asthmatics is limited, but specific allergen immunotherapy may be an appropriate adjunctive therapy when a clear relationship exists between symptoms, allergen exposure, and positivity to a skin test.Citation71

Asthma exacerbations are often sustained in the elderly by a variety of nonallergenic triggers, such as viral infections, pollutants, and drugs. Elderly asthmatics often perceive viral infections as common triggers and two thirds reported seasonal worsening in winter.Citation72 Patients with moderate to severe asthma should be advised to receive an influenza vaccination every year; they are safe and have a small risk of pulmonary complications.Citation73 From the 1991–2002 Medicare Survey, 72% of older subjects received influenza vaccinations.Citation74

Several epidemiologic studies suggest an association between outbreaks of asthma exacerbations and exposures to air pollutants;Citation75 environmental tobacco smoke is an important and modifiable air pollutant.Citation75 Surprisingly, active smoking is common among asthmatics.Citation76 Asthmatics who smoke often have poor disease controlCitation76 and diminished responsiveness to ICSCitation54,Citation77 and systemic corticosteroids.Citation78 It is generally believed that the damage from smoking has already been done in the elderly, but, although more beneficial when achieved early, quitting is always usefulCitation79 and has to be encouraged for all asthmatics who smoke, because clinically useful, traditional drugs used for support in smoking cessation have been safely and successfully used in the elderly.Citation80

Physical activity is important for patients with chronic respiratory diseases. It has been found that exercise training improves quality of life in older asthmatics.Citation81

Older asthmatics have an increased risk of comorbidities, as shown in .Citation82 In a survey, the prevalence of comorbidities in asthmatics was 22% higher than in healthy counterparts of similar age.Citation83 Several studies have also found an association between uncontrolled asthma and comorbidities and the proper treatment of some comorbidities may successfully contribute to asthma control.Citation82 On the other hand, treatment of other comorbidities, such as hypertension, congestive heart failure, arthrosis, and glaucoma can sustain or worsen asthma.Citation82 Possibly nonsteroidal anti-inflammatory drugsCitation84 and β-blockers,Citation85 including topical formulations,Citation86 are the most well-known drugs causing asthma exacerbations and should be avoided in patients with a history of unfavorable outcomes with these agents. Paracetamol and some selective cyclooxygenase-2 inhibitors, such as celecoxib and etoricoxib, and some newer beta-blockers may be a safer alternative.Citation87,Citation88

Table 5 Main asthma-related comorbidities

Role of education

The role of education in asthma management is essential and its key components are displayed in .Citation1Citation4

Table 6 Key components of a personalized asthma education program

The main goals of education are to achieve the patient’s self-management and improve adherence. Self-management requires not only the acquisition of knowledge and skills, but also behavior changes in order to achieve positive health effects.Citation89 Even if older asthmatics may be more prone to accept a passive approach and be less involved or not seek out information,Citation90 self-management is possible and effective even in the elderly and may also contribute to improve adherence.Citation93Citation95

Adherence is defined as the degree to which patient behaviors coincide with the recommendations of health care providers.Citation96 Adherence is a major problem for treatment of all chronic diseases, including asthma. Nonadherence significantly contributes to asthma mortality,Citation97 hospitalizations,Citation98 high health care costs,Citation95 and increased exacerbations.Citation99 It is useful to distinguish between intentional and unintentional nonadherence. Intentional nonadherence occurs when the patient decides either not to take the drug, to only take it from time to time, or to take a different dosage than prescribed.Citation96 Possibly, at similar baseline conditions, older asthmatics have the same degree of intentional nonadherence with respect to previous ages, even if in real life they often suffer from conditions predisposing them to nonadherence, such as polypharmacy and depression.Citation100,Citation101 Unintentional nonadherence occurs when a patient involuntarily does not follow medical prescriptions.Citation96 Poor inhaler technique is a variety of unintentional nonadherenceCitation96 and it is common in asthma, as the most important drugs used for its management are administered by inhalation. The effective use of inhalers is critically dependent upon the patient’s ability to utilize the device properly. Although inhaler misuse may be due to a poor device choice for an individual patient, more often it occurs for lack of proper education.Citation102 Unfortunately, poor inhaler technique is commonly observed for all inhaler devices, is associated with poor asthma control,Citation103 and with increased age.Citation102 The most important modifiable factors associated with improved inhaler use for both MDI and DPI are the provision of instructions (practical education being better than verbal) at the frst prescription and regular checks at each follow-up visit by trained heath caregivers.Citation102 Because the problem of inhaler misuse is neglected by patients and physicians, inhaler education should be an integral part of the routine management of any asthmatic patient.

Conclusion

Current guidelines do not include specific sections for the management of asthma in the elderly, supporting the view that drugs that are useful in managing asthma in the elderly are as effective as for other age groups. This is only partially evidence-based, as many randomized trials of treatment exclude older asthmatics.Citation104 According to this view, other reasons explain the greater percentage of uncontrolled asthma in the elderly, with increased morbidity and mortality.

A first cause is that many elderly patients perceive or tolerate substantial asthma symptoms, perhaps having low expectations about the degree of control that is possible. A second cause is that older asthmatics often suffer from many other comorbidities, which, directly or by treatment, may worsen the control of asthma. Possibly, patients and physicians often make tradeoffs with these comorbidities and do not treat asthma, considering it to be less dangerous. Importantly, guidelines do not include specific extensive sections for patients with multiple comorbidities and polypharmacy, a very common situation in the elderly; when guidelines describe possible interactions between diseases and with other drugs taken concomitantly, the discussion is superficial and limited to a few generic warnings, while drug–drug interactions often largely contribute to worsen asthma control in older adults. This calls for a shift in clinical research towards more pragmatic trials to generate more applicable evidence according to the peculiarities and the needs of older asthmatics.Citation105,Citation106 A third cause is poor adherence. It also includes inhaler misuse, which is particularly common in the elderly and often not contrasted efficiently.

We conclude that despite the fact that a variety of treatment options for good asthma management are available, in real life many elderly asthmatics suffer from poor disease control. The main reasons are that older asthmatics tolerate or do not perceive poor symptom control, are not encouraged to develop self-management, and have poor adherence to medications including common inhaler misuse. Concomitant comorbidities and/or related treatments may also contribute to poor asthma control. Identification and use of specific instruments addressed to evaluate asthma control in the elderly with concomitant comorbidities as well as measurements for improving self-management and adherence are needed for better asthma control in the elderly.

Disclosure

AS Melani has served as an advisory board member, has been reimbursed for speaker honoraria, and has received fees as a consultant for Chiesi, Menarini, Novartis, Mundipharma, GSK, Sanof-Aventis, and Artsana. There was no source of financial support for the present manuscript. The author reports no other conflicts of interest in this work.

References

  • National Heart, Lung, and Blood InstituteNational Asthma Education and Prevention ProgramExpert Panel Report 3: Guidelines for the Diagnosis and Management of AsthmaBethesdaNational Heart, Lung, and Blood Institute2007 Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdfAccessed March 31, 2013
  • British Thoracic SocietyScottish Intercollegiate Guidelines NetworkBritish Guideline on the Management of Asthma A national clinical guidelineEdinburghScottish Intercollegiate Guidelines Network2012 Available from: http://www.sign.ac.uk/pdf/sign101.pdfAccessed March 31, 2013
  • Global Initiative for Asthma [homepage on the Internet]Global strategy for asthma management and prevention [updated 2009] Available from: http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.htmlAccessed March 31, 2013
  • LougheedMDLeniereCDucharmeFMCanadian Thoracic Society Asthma Clinical AssembyCanadian Thoracic Society 2012 Guideline update: diagnosis and management of asthma in preschoolers, children, and adults: executive summaryCan Respir J2012196e81e8823248807
  • JonasDEWinesRCMDelMonteMOregon Health and Science UniversityDrug Class Review: Controller Medications for Asthma Final Update 1 Report 2011 Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032860/pdf/TOC.pdfAccessed March 31, 2013
  • ZureikMOrehekJDiagnosis and severity of asthma in the elderly: results of a large survey in 1,485 asthmatics recruited by lung specialistsRespiration200269322322812097765
  • SimpsonCRSheikhATrends in the epidemiology of asthma in England: a national study of 333,294 patientsJ R Soc Med201010339810620200181
  • EnrightPLMcClellandRLNewmanABGottliebDJLebowitzMDUnderdiagnosis and undertreatment of asthma in the elderly. Cardiovascular Health Study Research GroupChest1999116360361310492260
  • PlazaVSerra-BatllesJFerrerMMorejónEQuality of life and economic features in elderly asthmaticsRespiration2000671657010705265
  • BanerjiAClarkSAflaloMBlandaMPCydulkaRKCamargoCAJrProspective multicenter study of acute asthma in younger versus older adults presenting to the emergency departmentJ Am Geriatr Soc2006541485516420197
  • HananiaNAKingMJBramanSSAsthma in Elderly workshop participantsAsthma in the elderly: Current understanding and future research needs – a report of a National Institute on Aging (NIA) workshopJ Allergy Clin Immunol2011128Suppl 3S4S2421872730
  • TalrejaNBaptistAPEffect of age on asthma control: results from the National Asthma SurveyAnn Allergy Asthma Immunol20111061242921195941
  • TsaiCLDelclosGLHuangJSHananiaNACamargoCAJrAge-related differences in asthma outcomes in the United States, 1988–2006Ann Allergy Asthma Immunol2013110424024623535086
  • O’ByrnePMReddelHKErikssonGMeasuring asthma control: a comparison of three classification systemsEur Respir J201036226927620110397
  • ConnollyMJCrowleyJJCharanNBNielsonCPVestalREReduced subjective awareness of bronchoconstriction provoked by methacho-line in elderly asthmatic and normal subjects as measured on a simple awareness scaleThorax19924764104131496497
  • EkiciMApanAEkiciAErdemoğluAKPerception of bronchoconstriction in elderly asthmaticsJ Asthma200138869169611758898
  • GoemanDPO’HehirREJenkinsCScharfSLDouglassJA‘You have to learn to live with it’: a qualitative and quantitative study of older people with asthmaClin Respir J2007129910520298288
  • AllenSCVassalloMKhattabAThe threshold for sensing airflow resistance during tidal breathing rises in old age: implications for elderly patients with obstructive airways diseasesAge Ageing200938554855219589812
  • GibsonPGMcDonaldVMMarksGBAsthma in older adultsLancet2010376974380381320816547
  • JuniperEFO’ByrnePMGuyattGHFerriePJKingDRDevelopment and validation of a questionnaire to measure asthma controlEur Respir J199914490290710573240
  • NathanRASorknessCAKosinskiMDevelopment of the asthma control test: a survey for assessing asthma controlJ Allergy Clin Immunol20041131596514713908
  • VollmerWMMarksonLEO’ConnorEAssociation of asthma control with health care utilization and quality of lifeAm J Respir Crit Care Med19991605 Pt 11647165210556135
  • BuistASVollmerWMWilsonSRFrazierEAHaywardADA randomized clinical trial of peak fow versus symptom monitoring in older adults with asthmaAm J Respir Crit Care Med2006174101077108716931634
  • ColumboMWongBPanettieriRAJrRohrASAsthma in the elderly: the role of oxhaled nitric oxide measurementsRespir Med2013107578578723481173
  • NAEPP Working Group ReportConsiderations for Diagnosing and Managing Asthma in the ElderlyBethesdaNational Heart, Lung, and Blood Institute1996 Available from: http://msdh.ms.gov/msdhsite/_static/resources/2107.pdfAccessed on March 20, 2013
  • BarnesPJPedersenSBusseWWEfficacy and safety of inhaled corticosteroids. New developmentsAm J Respir Crit Care Med19981573 Pt 2S1S539520807
  • LipworthBJSystemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysisArch Intern Med1999159994195510326936
  • SzeferSJMartinRJKingTSAsthma Clinical Research Network of the National Heart Lung, and Blood InstituteSignificant variability in response to inhaled corticosteroids for persistent asthmaJ Allergy Clin Immunol2002109341041811897984
  • DerendorfHNaveRDrollmannACerasoliFWurstWRelevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthmaEur Respir J20062851042105017074919
  • MelaniASNebulized corticosteroids in asthma and COPD. An Italian appraisalRespir Care20125771161117422272733
  • PriceDMartinRJBarnesNPrescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational studyJ Allergy Clin Immunol2010126351151820692026
  • MüllerVGálffyGEszesNAsthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulationBMC Pulm Med2011114021762500
  • BrusselleGPechéRVan den BrandePVerhulstAHollandersWBruhwylerJReal-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking statusRespir Med2012106681181922357130
  • RankMAHaganJBParkMAThe risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trialsJ Allergy Clin Immunol2013131372472923321206
  • WenzelSEAsthma: defining of the persistent adult phenotypesLancet2006368953780481316935691
  • ThomasRAGreenRHBrithlingCEThe influence of age on induced sputum differential cell counts in normal subjectsChest200412661811181415596678
  • NavaratnamPJayawantSSPedersenCABalkrishnanRAsthma pharmacotherapy prescribing in the ambulatory population of the United States: evidence of nonadherence to national guidelines and implications for elderly peopleJ Am Geriatr Soc20085671312131718510581
  • SinDDTuJVInhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmaticsEur Respir J200117338038511405515
  • DolovichMBAhrensRCHessDRAmerican College of Chest Physicians; American College of Asthma, Allergy, and ImmunologyDevice selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and ImmunologyChest2005127133537115654001
  • PfeiferMAWeinbergCRCookDBestJDReenanAHalterJBDifferential changes of autonomic nervous system function with age in manAm J Med19837522492586881176
  • ConnollyMJCrowleyJJCharanNBNielsonCPVestalREImpaired bronchodilator response to albuterol in healthy elderly men and womenChest199510824014067634874
  • SearsMRTaylorDRPrintCGRegular inhaled beta-agonist treatment in bronchial asthmaLancet19903368728139113961978871
  • LazarusSCBousheyHAFahyJVAsthma Clinical Research Network for the National Heart, Lung, and Blood InstituteLong-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trialJAMA2001285202583259311368732
  • NelsonHSWeissSTBleeckerERYanceySWDorinskyPMSMART Study GroupThe Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterolChest20061291152616424409
  • BatemanEDBousheyHABousquetJGOAL Investigators GroupCan guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL studyAm J Respir Crit Care Med2004170883684415256389
  • StempelDAStoloffSWCarranza RosenzweigJRStanfordRHRyskinaKLLegorretaAPAdherence to asthma controller medication regimensRespir Med200599101263126716140227
  • PerrinKWilliamsMWijesingheMJamesKWeatherallMBeasleyRRandomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting beta-agonist inhaler therapy in asthmaJ Allergy Clin Immunol2010126350551020816187
  • McMahonAWLevensonMSMcEvoyBWMosholderADMurphyDAge and risks of FDA-approved long-acting β2-adrenergic receptor agonistsPediatrics20111285e1147e115422025595
  • BrozekJLKraftMKrishnanJALong-acting β2-agonist stepoff in patients with controlled asthmaArch Intern Med2012172181365137522928176
  • GoemanDPJenkinsCRCraneMABosnic-AnticevichSZDouglassJAUnmet needs of older people with asthma: cross-sectional surveyJ Asthma201148986587521967616
  • ChauhanBFDucharmeFMAnti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and childrenCochrane Database Syst Rev20125CD00231422592685
  • KorenblatPEKempJPSchergerJEMinkwitzMCMezzanotteWEffect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience And Pharmacoepidemiology Trial (ACCEPT)Ann Allergy Asthma Immunol200084221722510719780
  • PriceDBSwernATozziCAPhilipGPolosPEffect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trialAllergy200661673774216677244
  • LazarusSCChinchilliVMRollingsNJNational Heart Lung and Blood Institute’s Asthma Clinical Research NetworkSmoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthmaAm J Respir Crit Care Med2007175878379017204725
  • DucharmeFMLassersonTJCatesCJAddition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthmaCochrane Database Syst Rev20115CD00313721563136
  • TanRCorrenJOmalizumab in the treatment of asthmaExpert Rev Respir Med20115674775622082161
  • BuhlRFoxHBloggMReisnerCAdd-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of ageEur Respir J200526Suppl 4948SP418
  • LowePJRenardDOmalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgEBr J Clin Pharmacol201172230632021392073
  • CoxLLiebermanPWallaceDAmerican Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up reportJ Allergy Clin Immunol2011128121021221531014
  • TattersfieldAEPostmaDSBarnesPJExacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study GroupAm J Respir Crit Care Med1999160259459910430734
  • UllahMINewmanGBSaundersKBInfluence of age on response to ipratropium and salbutamol in asthmaThorax19813675235296458920
  • LipworthBJEmerging role of long-acting muscarinic antagonists for asthmaBr J Clin Pharmacol Epub3282013
  • SinghSLokeYKEnrightPLFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ2011342d321521672999
  • SimpsonJLPowellHBoyleMJScottRJGibsonPGClarithromycin targets neutrophilic airway inflammation in refractory asthmaAm J Respir Crit Care Med2008177214815517947611
  • SutherlandERKingTSIcitovicNNational Heart, Lung and Blood Institute’s Asthma Clinical Research NetworkA trial of clarithromycin for the treatment of suboptimally controlled asthmaJ Allergy Clin Immunol2010126474775320920764
  • BrusselleGGVandersticheleCJordensPAzithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trialThorax201368432232923291349
  • BatemanEDIzquierdoJLHarnestUEfficacy and safety of roflumilast in the treatment of asthmaAnn Allergy Asthma Immunol200696567968616729780
  • GildeaTRKhatriSBCastroMBronchial thermoplasty: a new treatment for severe refractory asthmaCleve Clin J Med201178747748521724932
  • SlavinRGHaselkornTLeeJHZhengBDenizYWenzelSETENOR Study GroupAsthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) studyAnn Allergy Asthma Immunol200696340641416597074
  • ScichiloneNCallariAAugugliaroGMarcheseMTogiasABelliaVThe impact of age on prevalence of positive skin prick tests and specific IgE testsRespir Med2011105565165821220195
  • BozekAIgnasiakBFilipowskaBJarzabJHouse dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitisClin Exp Allergy201343224224823331565
  • JacksonDJJohnstonSLThe role of viruses in acute exacerbations of asthmaJ Allergy Clin Immunol201012561178118720513517
  • PesekRLockeyRVaccination of adults with asthma and COPDAllergy2011661253120716316
  • Centers for Disease Control and Prevention (CDC)Influenza vaccination and self-reported reasons for not receiving influenza vaccination among Medicare beneficiaries aged > or = 65 years – United States, 1991–2002MMWR Morb Mortal Wkly Rep200453431012101515525898
  • BentayebMSimoniMBaizNGeriatric Study in Europe on Health Effects of Air Quality in Nursing Homes GroupAdverse respiratory effects of outdoor air pollution in the elderlyInt J Tuberc Lung Dis20121691149116122871325
  • BouletLPFitzGeraldJMMcIvorRAZimmermanSChapmanKRInfluence of current or former smoking on asthma management and controlCan Respir J200815527527918716691
  • TomlinsonJEMcMahonADChaudhuriRThompsonJMWoodSFThomsonNCEfficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthmaThorax200560428228715790982
  • ChaudhuriRLivingstonEMcMahonADThomsonLBorlandWThomsonNCCigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthmaAm J Respir Crit Care Med2003168111308131112893649
  • GellertCSchöttkerBBrennerHSmoking and all-cause mortality in older people: systematic review and meta-analysisArch Intern Med20121721183784422688992
  • TaitRJHulseGKWaterreusAEffectiveness of a smoking cessation intervention in older adultsAddiction2007102114815517207132
  • TurnerSEastwoodPCookAJenkinsSImprovements in symptoms and quality of life following exercise training in older adults with moderate/severe persistent asthmaRespiration201181430231020501982
  • BouletLPBoulayMÈAsthma-related comorbiditiesExpert Rev Respir Med20115337739321702660
  • GershonASGuanJWangCVictorJCToTDescribing and quantifying asthma comorbidity: a population studyPLoS One201275e3496722586445
  • SzczeklikAAspirin-induced asthma: a tribute to John Vane as a source of inspirationPharmacol Rep201062352652920631417
  • AshrafanHViolarisAGBeta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpo intPrim Care Respir J200514523624116701736
  • OdehMOlivenABassanHTimolol eyedrop-induced fatal bronchospasm in an asthmatic patientJ Fam Pract199132197981985142
  • Martin-GarcíaCHinojosaMBergesPCamachoEGarcía-RodriguezRAlfayaTCelecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patientsJ Invest Allergol Clin Immunol20031312025
  • HananiaNASinghSEl-WaliRThe safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot studyPulm Pharmacol Ther200821113414117703976
  • GibsonPGPowellHCoughlanJSelf-management education and regular practitioner review for adults with asthmaCochrane Database Syst Rev20031CD00111712535399
  • SchneiderAKörnerTMehringMWensingMElwynGSzecsenyiJImpact of age, health locus of control and psychological co-morbidity on patients’ preferences for shared decision making in general practicePatient Educ Couns200661229229815896943
  • PatelRRSaltounCAGrammerLCImproving asthma care for the elderly: a randomized controlled trial using a simple telephone interventionJ Asthma2009461303519191134
  • BaptistAPRossJAYangYSongPXClarkNMA randomized controlled trial of a self-regulation intervention for older adults with asthmaJ Am Geriatr Soc201361574775323617712
  • GoemanDPSanciLAScharfSLImproving general practice consultations for older people with asthma: a cluster randomised control trialMed J Aust2009191211311719619101
  • BozekAJarzabJAdherence to asthma therapy in elderly patientsJ Asthma201047216216520170323
  • WilsonSRStrubPBuistASBetter Outcomes of Asthma Treatment (BOAT) Study GroupShared treatment decision making improves adherence and outcomes in poorly controlled asthmaAm J Respir Crit Care Med2010181656657720019345
  • World Health OrganizationAdherence to Long-term Therapies: Evidence for ActionGenevaWorld Health Organization2003 Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/Accessed March 20, 2013
  • HarrisonBStephensonPMohanGNasserSAn ongoing Confidential Enquiry into asthma deaths in the Eastern Region of the UK, 2001–2003Prim Care Respir J200514630331316701746
  • WilliamsLKPladevallMXiHRelationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthmaJ Allergy Clin Immunol200411461288129315577825
  • WilliamsLKPetersonELWellsKQuantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherenceJ Allergy Clin Immunol201112861185119122019090
  • DiMatteoMRLepperHSCroghanTWDepression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherenceArch Intern Med2000160142101210710904452
  • KrauskopfKASofianouAGoelMSDepressive symptoms, low adherence, and poor asthma outcomes in the elderlyJ Asthma201350326026623294120
  • SestiniPCappielloVAlianiMAssociazione Italiana Pneumologi Ospedalieri Educational GroupPrescription bias and factors associated with improper use of inhalersJ Aerosol Med200619212713616796537
  • MelaniASBonaviaMCilentiVGruppo Educazionale Associazione Italiana Pneumologi OspedalieriInhaler mishandling remains common in real life and is associated with reduced disease controlRespir Med2011105693093821367593
  • TraversJMarshSWilliamsMExternal validity of randomised controlled trials in asthma: to whom do the results of the trials apply?Thorax200762321922317105779
  • KrishnanJASchatzMApterAJA call for action: Comparative effectiveness research in asthmaJ Allergy Clin Immunol2011127112312720855111
  • PriceDHillyerEVvan der MolenTEfficacy versus effectiveness trials: informing guidelines for asthma managementCurr Opin Allergy Clin Immunol2013131505723242115